Eli Lilly reduces prices of Zepbound by way of its LillyDirect platform

Eli Lilly on Monday introduced new worth cuts for its fashionable weight reduction drug Zepbound, broadening entry for sufferers and driving better use of the corporate’s digital healthcare platform, LillyDirect.

Single-dose vials of Zepbound bought by way of the Zepbound Self Pay Journey Program on LillyDirect will now value $299 per 30 days – down from $349 – for sufferers with a legitimate prescription.

The 5-milligram dose may also be priced at $399 per 30 days, down from $499. All different accepted doses will value $449 per 30 days, Eli Lilly mentioned.

LillyDirect, which launched in early 2024, permits some customers who lack insurance coverage or who’re insured or lack sufficient protection to entry Zepbound and Mounjaro instantly from Eli Lilly by way of its Zepbound Self Pay Journey Program. 

TRUMP ANNOUNCES DEAL WITH DRUGMAKERS TO LOWER COST OF WEIGHT LOSS DRUGS

Single-dose vials of Zepbound will now value $299 per 30 days. (Shelby Knowles/Bloomberg by way of Getty Photographs / Getty Photographs)

Common costs per 30 days when not bought by way of the Zepbound Self-Pay Journey Program are $599 for 7.5 milligrams, $699 for 10 milligrams, $849 for 12.5 milligrams, $1,049 for 15 milligrams, in line with the pharmaceutical large.

WEGOVY, OZEMPIC: THE BARRIERS TO ACCESSING THESE WEIGHT LOSS DRUGS

The transfer comes lower than a month after Eli Lilly introduced plans to decrease costs for Zepbound multi-dose pens, although that’s nonetheless topic to approval by the Meals and Drug Administration (FDA). Beginning as early as April 2026, Medicare sufferers can pay not more than $50 a month for Zepbound offered in a multi-dose pen and for orforglipron, Lilly’s once-a-day weight reduction tablet, so long as each medicine are accepted by the FDA. 

Eli Lilly rival Novo Nordisk makes its personal weight reduction medicine, Wegovy and Ozempic. (Shelby Knowles/Bloomberg by way of Getty Photographs)

For self-pay sufferers, the Zepbound multi-dose pen shall be accessible on the lowest dose at $299, with further doses as much as $449. When sufferers refill their multi-dose pen prescription on the LillyDirect digital well being platform, they may pay not more than $449. Orforglipron shall be accessible with the bottom dose beginning at $149 with further doses as much as $399, the corporate beforehand mentioned.

MAJOR HEALTH INSURERS SCALING BACK MEDICARE ADVANTAGE OFFERINGS IN 2026

Eli Lilly and Novo Nordisk have launched their very own direct-to-consumer platforms geared toward increasing affected person entry by limiting the limitations new sufferers face. Whereas each corporations say these platforms will assist new sufferers get entry to their medicines, in addition they give every firm a aggressive edge.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Novo Nordisk launched its platform, NovoCare Pharmacy, in March, permitting sufferers who couldn’t afford the usual record worth or lacked insurance coverage protection for its weight reduction medicine Wegovy and Ozempic.